| Autor: |
Merryn Voysey, Gaurav Kwatra, Elizabeth J. Kelly, Eck Sv, Houriiyah Tegally, Alex Sigal, Oelofse S, Shaun Barnabas, C Taoushanis, de Oliveira T, Hylton Errol Rodel, Tonya Villafana, M M Groenewald, Aylin Oommen Jose, Teresa Lambe, Alane Izu, Masebole Masenya, Shi-Hsia Hwa, A Moultrie, K Molapo, Keertan Dheda, Plessis Jd, Nicholas M. Durham, Anthonet Koen, Penelope L. Moore, Mduduzi Masilela, Constantinos Kurt Wibmer, Sarah C. Gilbert, Khatija Ahmed, Jinal N. Bhiman, Lee Fairlie, Carmen Briner, Bhikha S, S D Padayachee, As’ad E. Bhorat, E Horne, Clare L. Cutland, Q E Bhorat, F Patel, Parvinder K. Aley, Shabir A. Madhi, Aliasgar Esmail, Asha Thombrayil, Andrew J. Pollard, L Rossouw, M Malahleha, McKenzie S, Sureshnee Pillay, S Rhead, Baillie, Laubscher M |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.02.10.21251247 |
| Popis: |
BackgroundAssessing safety and efficacy of Covid-19 vaccines in different populations is essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern including the B.1.351 (501Y.V2) variant first identified in South Africa.MethodsWe conducted a randomized multicentre, double blinded controlled trial on safety and efficacy of ChAdOx1-nCoV19 in HIV-uninfected people in South Africa. Participants age 18 to 10viral particles or placebo (0.9%NaCl) 21-35 days apart. Post 2nd-dose serum samples (n=25) were tested by pseudotyped (PSVNA) and live virus (LVNA) neutralization assays against the D614G and B.1.351 variants. Primary endpoints were safety and vaccine efficacy (VE) >14 days following second dose against laboratory confirmed symptomatic Covid-19.Results2026 HIV-uninfected adults were enrolled between June 24thand Nov 9th, 2020; 1010 and 1011 received at least one dose of placebo or vaccine, respectively. Median age was 31 years. The B.1.351 variant showed increased resistance to vaccinee sera using the PSVNA and LVNA. In the primary endpoint analysis, 23/717 (3.2%) placebo and 19/750 (2.5%) vaccine recipients developed mild-moderate Covid-19; VE 21.9% (95%Confidence Interval: −49.9; 59.8). Of the primary endpoint cases, 39/42 (92.9%) were the B.1.351 variant; against which VE was 10.4% (95%CI: −76.8; 54.8) analyzed as a secondary objective. The incidence of serious adverse events was balanced between the vaccine and placebo groups.ConclusionsA two-dose regimen of ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however, VE against severe Covid-19 is undetermined.(Funded by The Bill & Melinda Gates Foundation and South African Medical Research Council; ClinicalTrails.gov number,NCT04444674). |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
